Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed, TAS-102, and Bevacizumab in Refractory mCRC
NCT04683965Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pemetrexed in metastatic colorectal cancer (mCRC), sponsored by Jiangsu Provincial People's Hospital. Status: unknown.
02
Drugs
pemetrexed
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04683965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04683965.